经口腔内镜与机器人甲状腺切除术治疗甲状腺癌:中期肿瘤学结局
该研究回顾了2017年7月至2021年11月接受经口腔前庭入镜甲状腺切除术(TOETVA)或经口机器人甲状腺切除术(TORT)的甲状腺癌患者,随访至2022年12月。共115例患者接受122次手术(57次TOETVA、65次TORT),TORT手术时间较TOETVA长,两组围术期并发症无差异。中期随访平均37.88±12.42个月,生存率100%,可接受反应率98.2%。
要点
- TORT手术时间长于TOETVA:甲状腺叶切除279 vs 196分钟,双侧全甲状腺切除375 vs 279分钟,p均<0.001。
- 两组围术期并发症无差异,无经口转开放手术。
- 中期随访平均37.88±12.42个月,生存率100%,可接受反应率98.2%。
核心结论
- 经口腔内镜与机器人甲状腺切除术在早期分化型甲状腺癌选定队列中安全,并取得良好的中期肿瘤学结局。
研究设计与样本
- 回顾性分析2017年7月至2021年11月接受TOETVA或TORT的患者,随访肿瘤学结局至2022年12月,分析围术期手术与中期肿瘤学结局。
- 共115例患者接受122次手术,其中57次TOETVA、65次TORT,包括7例分化型甲状腺癌(DTC)全甲状腺切除,分期I-II期,包括T1-T3、N0-N1a,初始低至高风险组。
主要发现
- 无经口转开放手术。
- TORT手术时间长于TOETVA:甲状腺叶切除中位279(250,318)vs 196(173,253)分钟,p<0.001;双侧全甲状腺切除375(309,433)vs 279(238,312)分钟,p<0.001。
- 两组围术期并发症无差异。
- 经口二次入路全甲状腺切除安全。
- TOETVA与TORT取得良好肿瘤学结局,中期随访平均37.88±12.42个月,生存率100%,可接受反应(极佳与不确定反应)率98.2%。
关键数值与推荐
- TORT甲状腺叶切除中位手术时间279(250,318)分钟 vs TOETVA 196(173,253)分钟,p<0.001。
- TORT双侧全甲状腺切除中位手术时间375(309,433)分钟 vs TOETVA 279(238,312)分钟,p<0.001。
- 中期随访平均37.88±12.42个月,生存率100%,可接受反应率98.2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Traditional open thyroidectomy is the surgical standard for thyroid cancer; however, it inevitably leaves a visible scar on the neck and affects the patient's quality of life. Therefore, to avoid making a neck incision, the transoral endoscopic thyroidectomy vestibular approach (TOETVA) and transoral robotic thyroidectomy (TORT) have been developed recently, and the surgical outcomes of these techniques are as favorable as open surgery for benign disease. Additionally, positive short-term surgical outcomes have also been achieved in a few patients with thyroid cancer. However, no data on the mid-to-long-term recurrence and survival rates of transoral thyroidectomy in thyroid cancer are available. Therefore, in this study, we analyzed the surgical outcomes and mid-term oncological results of the TOETVA and TORT in patients with thyroid cancer. METHODS: We reviewed patients who had received TOETVA or TORT between July 2017 and November 2021 and followed up on their oncological outcomes until December 2022. Perioperative surgical and mid-term oncological outcomes were analyzed. RESULTS: The 115 patients underwent 122 operations (57 TOETVAs and 65 TORTs), including seven complete thyroidectomies for differentiated thyroid cancer (DTC), Stage I-II, including T1-T3, N0-N1a, and initial low- to high-risk groups. There was no conversion from transoral to open surgery. TORT required a longer operating time (median [interquartile range]) than TOETVA (lobectomy: 279 [250, 318] vs. 196 [173, 253] min, p < 0.001; bilateral total thyroidectomy: 375 [309, 433] vs. 279 [238, 312] min, p < 0.001); however, no difference was found between the two groups regarding perioperative complications. Complete thyroidectomy with a second transoral approach was safe. TOETVA and TORT achieved favorable oncological outcomes with 100% survival and 98.2% acceptable response (excellent and indeterminate response) during a mean 37.88 ± 12.42 months mid-term follow-up. CONCLUSIONS: Transoral endoscopic and robotic thyroidectomy was safe and achieved favorable mid-term oncological outcomes in a selected cohort of patients with early-stage DTC.
引用
- Chen YH, Chao WP, Wang SH, et al. Transoral endoscopic and robotic thyroidectomy for thyroid cancer: the mid-term oncological outcome. Surg Endosc. 2023. PMID: 37605012. doi:10.1007/s00464-023-10339-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。